Skip to main content

Main menu

  • About Us
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
    • Strategic Plan
  • Our Research
    • Research Focus
      • Brain Health
      • Cancer
      • Cardiovascular Conditions and Diseases
      • Digital Health
      • Health Policy
      • Immunity and Infectious Diseases
      • Joint Health and Mobility
      • Respiratory and Lung Health
      • Spinal Cord Injury and Rehabilitation
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Aging SMART
      • Centre for Cardiovascular Innovation
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Lung Health
      • Djavad Mowafaghian Centre for Brain Health
      • Immunity and Infection Research Centre
      • International Collaboration On Repair Discoveries
      • Ovarian Cancer Research Centre
      • Vancouver Prostate Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Skin Research Program
      • Other Research Focus Areas
    • News and Stories
    • Researcher Directory
    • Events and Workshops
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
    • Starting Your Project
      • Research Facilitation
      • Awards and Funding
      • Grant Management
      • Operational Approval
    • Developing Your Project
      • Clinical Trials Administration
      • Clinical Research Unit
      • CST Cerner at VCH
      • Research Privacy
      • Financial Policies and Procedures
    • Additional Support
      • Education and Training
      • Communications and Branding
      • Media Relations
      • Study Recruitment Support
      • Innovation and Industry Partnership
    • Internal Awards
    • Clinical Research
    • Innovation and Partnership
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Our Research
  3. News and Stories
  4. The invisible lightness of healing

The invisible lightness of healing

Stories Nov 3, 2022 3 minutes

Phototherapy deemed low risk for atopic eczema patients who find the treatments simple and effective.

Benefits of exposing skin to ultraviolet light for people with atopic eczema far outweighs the risk, according to a study that will leave clinicians to rest easy, knowing that prescribed phototherapy does more good than harm.

The study, published in the Journal of the American Academy of Dermatology, was authored by Dr. Tashmeeta Ahad, a clinician-scientist within the Skin Research Program at Vancouver Coastal Health Research Institute (VCHRI). 

Its findings support the use of phototherapy — including narrowband UVB, broadband UVB and concurrent UVA plus broadband UVB — as a non-carcinogenic treatment for atopic eczema. Ahad, Dr. Sunil Kalia, principal investigator, and Elle Wang, a graduate student who worked on the study, found that phototherapy does not lead to higher incidences of melanoma, squamous cell carcinoma or basal cell carcinoma in people with this skin disorder. 

“Our findings reassure people that phototherapy is a safe treatment option that does not increase the risk of skin cancer. We now have a better idea that the harms posed by exposure to UV lights are limited under controlled circumstances.” 

Dr. Tashmeeta Ahad is a clinical instructor and director of Translational Photomedicine Research in the University of British Columbia (UBC) Department of Dermatology and Skin Science. She is also a clinician-scientist with the Photomedicine Institute. 

Ultraviolet phototherapy is one of the primary tools used by dermatologists to treat patients with atopic eczema, the most common form of the skin disorder that causes it to become itchy, dry and cracked. It affects up to 25 per cent of children and up to two per cent of the adult population. 

Ahad explains it is common for patients to question their skin cancer risks even though they are seeing beneficial results from the therapy. “That is the dilemma,” Ahad says. “People will come in for a lot of phototherapy sessions, but we do not really understand if that is increasing their risk of skin cancer. That has been a worry for a lot of patients.” 

Patients with atopic eczema typically receive phototherapy treatments two-to-three-times weekly in a whole-body light booth. With exposure ranging from seconds to minutes, and in repeated sessions.

While the healing power of light has been anecdotally recognized for thousands of years, no one yet fully understands how light affects our cells or the chemicals they produce when exposed to light. “We think ultraviolet light helps to suppress inflammation in the skin by targeting immune cells and cytokines that play a role in eczema and other skin disorders.”   

No harm from controlled exposure to phototherapy

Ahad’s study sought to investigate whether patients with eczema treated with ultraviolet phototherapy have a higher risk of skin cancer. 

The research team examined the treatment records of 925 patients who received phototherapy at the Vancouver-based centre between 1996 and 2018. Skin cancer records were validated via pathology biopsy reports. Age-standardized incidence rates of skin cancer developing in patients post phototherapy were then compared to age-standardized incidence rates of melanoma, squamous cell carcinoma and basal cell carcinoma in the British Columbia general population.

The clinical study — funded and supported by the Eczema Society of Canada and Canadian Dermatology Foundation — also evaluated skin cancer risk, based on the total amount of phototherapy received. No significant difference was seen in incidence rates of skin cancer in patients treated with fewer than 25 sessions versus those patients treated with more than 100 phototherapy sessions. 

"For people who have had phototherapy treatments, the study revealed that the likelihood of developing skin cancers was no greater than that of the general population.”

Overall, the findings will not only serve to reassure patients of treatment safety, but will also reassure clinicians that the phototherapy treatments helping their patients are not also doing any long-term harm.

 

Researchers

Tashmeeta Ahad
Sunil Kalia

Related Articles

Ask an expert: Do I need to wear sunscreen in the winter?

Moving the dial on darker skin tone representation in medicine

Ask an expert: How can I stay safe in the sun?

Share:

  • Facebook
  • Linkedin
  • Twitter
  • Email

Related Research Centres/Programs

Skin Research Program

Get the latest research headlines in your inbox

Subscribe

Recent News and Stories

Type
Announcement

Investigator Awards 2023 Recipients

Mar 21, 2023 award
Type
Stories

Ask an expert: Is my menstrual pain normal, or could I have endometriosis?

Mar 16, 2023 women, endometriosis, preventative
Type
Stories

Honing in on precision treatments for endometriosis

Mar 14, 2023 genetics, treatment options
See more news

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • Twitter
  • LinkedIn

© 2023 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy